Tsai Capital Corp Purchases 248 Shares of Danaher Co. (NYSE:DHR)

Tsai Capital Corp increased its position in shares of Danaher Co. (NYSE:DHR) by 1.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 14,397 shares of the conglomerate’s stock after acquiring an additional 248 shares during the period. Danaher makes up approximately 2.4% of Tsai Capital Corp’s holdings, making the stock its 14th largest holding. Tsai Capital Corp’s holdings in Danaher were worth $3,305,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its stake in Danaher by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate’s stock worth $13,715,641,000 after buying an additional 315,912 shares in the last quarter. Norges Bank bought a new stake in shares of Danaher during the 4th quarter worth $2,130,740,000. Bank of New York Mellon Corp grew its position in Danaher by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock worth $1,971,609,000 after acquiring an additional 441,012 shares in the last quarter. Fisher Asset Management LLC increased its stake in Danaher by 0.6% in the fourth quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate’s stock valued at $1,051,097,000 after acquiring an additional 26,305 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Danaher by 3.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate’s stock valued at $933,524,000 after purchasing an additional 135,047 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Down 2.1 %

Shares of DHR opened at $205.69 on Friday. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm’s 50-day moving average price is $214.57 and its 200-day moving average price is $236.90. The firm has a market capitalization of $147.01 billion, a price-to-earnings ratio of 38.96, a PEG ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the business posted $2.09 EPS. Sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is 24.24%.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on DHR shares. Scotiabank started coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Barclays reduced their price target on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Robert W. Baird cut their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. JPMorgan Chase & Co. decreased their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, Stifel Nicolaus upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 price target for the company in a research report on Friday, March 14th. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $278.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.